ReviewFrontiers in gastroenterology (Lausanne, Switzerland)2022
European Registry on
Review in Frontiers in gastroenterology (Lausanne, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) toAntibiotics (Basel, Switzerland) · 2025Article
- The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations.Nature communications · 2025Article
- TargetingNutrients · 2025Review
- Article
- Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.United European gastroenterology journal · 2024Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Comparison of the management of Helicobacter pylori infection between the older and younger European populations.Scientific reports · 2023Article
- Analysis of Clinical Phenotypes through Machine Learning of First-LineAntibiotics (Basel, Switzerland) · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ideal treatment approach for Methods: All research studies published between 2013 and 2022, evaluating any information related to Results: Overall, 26 studies have been published to date, where 12 evaluated the overall European data and the remaining were performed locally among the 28 participating countries. Eighteen studies evaluated the effectiveness of first- and/or second-line treatment, where one focused on penicillin allergic patients, six focused on specific treatment schemes, one evaluated the role of statins as a concomitant drug when combined with the eradication therapy, one assessed the adverse event profile of treatments, one evaluated the bacterial antibiotic resistance trends, and a last one reported on the common mistakes in routine clinical practice of European gastroenterologists. Conclusion: The Hp-EuReg had a major influence on the routine clinical practice of European gastroenterologists, improving
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.